Less is more: Reducing the reliance on animal models for nausea and vomiting research

British Journal of Pharmacology

Volumn 157, Issue 6, 2009, Pages 863-864

  Robinson, V ^a  

^a National Centre for the Replacement   (United Kingdom)

Author keywords

3Rs; Alternative; Animal models; In vitro; Nausea; Reduction; Refinement; Replacement; Vomiting

Indexed keywords

CLINICAL RESEARCH; COMPUTER MODEL; DISEASE MODEL; DRUG INDUSTRY; ENVIRONMENTAL PROTECTION; EXPERIMENTAL MODEL; NAUSEA; NONHUMAN; NOTE; PRIORITY JOURNAL; RESEARCH ETHICS; SKIN TEST; TISSUE ENGINEERING; VOMITING;

ANIMAL EXPERIMENTATION; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NAUSEA; TISSUE ENGINEERING; VOMITING;

EID: 70350337072     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00280.x     Document Type: Note

References (11)

1. ECVAM (2008). Validated models-Two in vitro skin irritation tests: Epi-Derm SIT and SkinEthic RHE assay. Available at: http://ecvam.jrc.it/ (accessed 10 February 2009).
2. European Commission and Pharmaceutical Industry (2007). Innovative Medicines Initiative. Available at: http://imi.europa.eu/index-en. html (accessed 10 February 2009).
3. Hoffmann IS, Roa M, Torrico F, Cubeddu LX (2003). Ondansetron and metformin-induced gastrointestinal side effects. Am J Ther 10: 447-451.
4. Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PLR (2009). Opportunities for the replacement of animals in the study of rausea and vomiting. Br J Pharmacol 157: 865-880.
5. Kidd DA, Johnson M, Clements J (2007). Development of an in vitro corrosion/irritation prediction assay using the EpiDerm skin model. Toxicol In Vitro 21: 1292-1297.
6. Lelievre D, Justine P, Christiaens F, Bonaventure N, Coutet J, Marrot L et al. (2007). The EpiSkin phototoxicity assay (EPA): development of an in vitro tiered strategy using 17 reference chemicals to predict phototoxic potency. Toxicol In Vitro 21: 977-995.
7. NC3Rs (2009). Survey of UK licence holders. Available at: http:// www.nc3rs.org.uk/opinionsurvey (accessed 10 February 2009).
8. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761-775.
9. Spina D (2008). PDE4 inhibitors: current status. Br J Pharmacol 155: 308-315.
10. US Food and Drug Administration (2004). Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. Available at: http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.pdf (accessed 10 February 2009).
11. US National Research Council (NRC) Committee on Toxicity and Assessment of Environmental Agents (2007). Toxicity testing in the 21st century: a vision and a strategy. Available at: http:// dels.nas.edu/dels/rpt-briefs/Toxicity- Testing-final.pdf (accessed 10 February 2009).